Want to see OTLK full AI Analyst Report?
OTLK Stock Chart & Stats
$1.40
-$0.07(-5.34%)
At close: 4:00 PM EDT
$1.40
-$0.07(-5.34%)
Day’s Range― - ―
52-Week Range$0.16 - $3.39
Previous CloseN/A
Volume462.68K
Average Volume (3M)13.68M
Market Cap
$157.56M
Enterprise Value$224.61
Total Cash (Recent Filing)$11.24M
Total Debt (Recent Filing)$18.43M
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Dec 18, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.22
Shares Outstanding243,447,560
10 Day Avg. Volume13,491,520
30 Day Avg. Volume13,678,892
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-0.84
Price to Sales (P/S)19.10
P/FCF Ratio-0.52
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.20Price Target Upside271.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.5
Revenue Forecast (FY)$2.46M
Bulls Say, Bears Say
Bulls Say
Regulatory ApprovalFDA approval removes the central regulatory barrier and enables U.S. commercialization. The product’s ophthalmic formulation and potential biologics exclusivity provide a differentiated platform for building a durable position in retinal care.
Large Addressable MarketA large existing retina market and substantial off-label bevacizumab usage create a meaningful conversion opportunity. If physicians and payers adopt LYTENAVA, the company can develop recurring product revenue rather than remain dependent on development funding.
Clinical DifferentiationThe registrational efficacy result supports a differentiated clinical message for LYTENAVA. Stronger visual-acuity outcomes can improve physician confidence and help the company compete for patients in a crowded anti-VEGF treatment market.
Bears Say
Stressed Balance SheetNegative equity and sharply higher debt indicate a severely impaired capital position. This reduces financial flexibility, raises dependence on external capital, and leaves less room to absorb delays or cost overruns during the commercial launch.
Persistent Cash BurnSustained operating and free-cash-flow deficits mean commercialization must fund both ongoing losses and launch investment. Continued cash consumption increases dilution or financing risk if product adoption, reimbursement, or launch timing falls short.
Commercial Execution RiskLYTENAVA must compete with lower-cost biosimilars and compounded bevacizumab while navigating payer and patient affordability barriers. Delayed coding or unfavorable reimbursement could materially weaken conversion, pricing power, and the expected revenue ramp.
Outlook Therapeutics News
OTLK FAQ
What was Outlook Therapeutics’s price range in the past 12 months?
Outlook Therapeutics lowest stock price was $0.16 and its highest was $3.39 in the past 12 months.
What is Outlook Therapeutics’s market cap?
Outlook Therapeutics’s market cap is $157.56M.
When is Outlook Therapeutics’s upcoming earnings report date?
Outlook Therapeutics’s upcoming earnings report date is Dec 18, 2026 which is in 115 days.
How were Outlook Therapeutics’s earnings last quarter?
Outlook Therapeutics released its earnings results on Aug 14, 2026. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.08 by -$0.06.
Is Outlook Therapeutics overvalued?
According to Wall Street analysts Outlook Therapeutics’s price is currently Undervalued.
Does Outlook Therapeutics pay dividends?
Outlook Therapeutics does not currently pay dividends.
What is Outlook Therapeutics’s EPS estimate?
Outlook Therapeutics’s EPS estimate is -0.07.
How many shares outstanding does Outlook Therapeutics have?
Outlook Therapeutics has 243,447,560 shares outstanding.
What happened to Outlook Therapeutics’s price movement after its last earnings report?
Outlook Therapeutics reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.08. Following the earnings report the stock price went down -14.865%.
Which hedge fund is a major shareholder of Outlook Therapeutics?
Currently, no hedge funds are holding shares in OTLK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Outlook Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.20 (271.43% Upside)
$5.20 (271.43% Upside)
Blogger Sentiment
Bullish
OTLK Sentiment 86%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $7.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 2.4%
Last 30 Days ▲ 4.3%
Last 30 Days ▲ 4.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-29.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
16.94%
Trailing 12-Months
Company Description
Outlook Therapeutics
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
OTLK Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely positive tone based on a transformational FDA approval, strong registrational efficacy data, clear commercial planning and recent financing to fund the U.S. launch. However, material risks remain: competitive pricing pressure from biosimilars, European commercialization challenges, reimbursement and patient affordability concerns, reliance on a J‑code and near‑term liquidity that required a public offering. Management positions the company to execute a measured launch with conservative forecasts and contingency upside if compounded bevacizumab availability changes.View all OTLK earnings summariesOTLK Stock 12 Month Forecast
Average Price Target
$5.20
▲(271.43% Upside)
Technical Analysis
Ownership Overview
10.51% Insiders
0.92% Mutual Funds
1.79% Other Institutional Investors
85.01% Public Companies and
Individual Investors